Inhibitor Therapeutics (INTI) Change in Accured Expenses (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Change in Accured Expenses came in at -$384781.0 in Q1 2026, up 39.96% YoY from -$274918.7 in Q1 2025, and down 156.75% on a QoQ basis from $678042.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Change in Accured Expenses data on file, last reported at -$384781.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 39.96% year-over-year to -$384781.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284614.0 (up 426.67% YoY) and the FY2025 annual result came in at $28502.0, down 35.88% from the prior year.
- Change in Accured Expenses declined to -$384781.0 in Q1 2026, from $678042.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $678042.0 in Q4 2025 to a low of -$640893.0 in Q1 2025.
- A 5-year average of $13140.4 and a median of $9032.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 34393.06% — and 2023, when it sank 799.94%.
- Tracing INTI's Change in Accured Expenses over 5 years: stood at $59327.0 in 2022, then soared by 757.49% to $508724.0 in 2023, then surged by 30.73% to $665059.0 in 2024, then increased by 1.95% to $678042.0 in 2025, then plunged by 156.75% to -$384781.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$384781.0 (Q1 2026), $678042.0 (Q4 2025), and -$53896.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -208,216.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384,781.00 |
| Mar 31, 2026 | -384,781.00 |
| Dec 31, 2025 | 678,042.00 |
| Dec 31, 2025 | 678,042.00 |
| Sep 30, 2025 | -53,896.00 |
| Sep 30, 2025 | -53,896.00 |
| Jun 30, 2025 | 45,249.00 |
| Jun 30, 2025 | 45,249.00 |
| Mar 31, 2025 | -640,893.00 |
| Mar 31, 2025 | -640,893.00 |
| Dec 31, 2024 | 665,059.00 |
| Dec 31, 2024 | 665,059.00 |
| Sep 30, 2024 | 9,032.00 |
| Sep 30, 2024 | 9,032.00 |
| Jun 30, 2024 | -120,323.00 |
| Jun 30, 2024 | -120,323.00 |
| Mar 31, 2024 | -509,314.00 |
| Mar 31, 2024 | -509,314.00 |
| Dec 31, 2023 | 508,724.00 |
| Dec 31, 2023 | 508,724.00 |